TCGA-BH-A0B2-01A-11R-A10J-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.750
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- INFLAMMATORY_RESPONSE+0.420
- COMPLEMENT+0.410
- KRAS_SIGNALING_UP+0.390
- COAGULATION+0.350
- IL6_JAK_STAT3_SIGNALING+0.340
- IL2_STAT5_SIGNALING+0.330
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.410
- MTORC1_SIGNALING-0.400
- MITOTIC_SPINDLE-0.390
- PROTEIN_SECRETION-0.310
- MYC_TARGETS_V2-0.300
- OXIDATIVE_PHOSPHORYLATION-0.280
- DNA_REPAIR-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG311 | — | — | 0.900 |
| 2 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.899 |
| 3 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.898 |
| 4 | R194 | — | — | 0.897 |
| 5 | TCGA-AC-A2FE-01A-11R-A19W-07 | — | A | 0.892 |
| 6 | MDT-AP-1152 | Med | Medulloblastoma | 0.891 |
| 7 | SRR26320092 | — | — | 0.886 |
| 8 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.882 |
| 9 | SRR2771286 | — | — | 0.882 |
| 10 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.750 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |